Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer

[1]  Yusuke Nakamura,et al.  Characterization of the human p57KIP2 gene: Alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis , 1996, Human Genetics.

[2]  M. Emi,et al.  Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer , 2003, Oncogene.

[3]  C. Junien,et al.  Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith–Wiedemann syndrome , 2003, Journal of medical genetics.

[4]  N. Niikawa,et al.  Loss of CpG methylation is strongly correlated with loss of histone H3 lysine 9 methylation at DMR-LIT1 in patients with Beckwith-Wiedemann syndrome. , 2003, American journal of human genetics.

[5]  R. Weksberg,et al.  Insulator and silencer sequences in the imprinted region of human chromosome 11p15.5. , 2003, Human molecular genetics.

[6]  C. Kanduri,et al.  Bidirectional Silencing and DNA Methylation-sensitive Methylation-spreading Properties of the Kcnq1 Imprinting Control Region Map to the Same Regions* , 2003, The Journal of Biological Chemistry.

[7]  S. Tilghman,et al.  A differentially methylated region within the gene Kcnq1 functions as an imprinted promoter and silencer. , 2003, Human molecular genetics.

[8]  T. Mukai,et al.  Domain regulation of imprinting cluster in Kip2/Lit1 subdomain on mouse chromosome 7F4/F5: large-scale DNA methylation analysis reveals that DMR-Lit1 is a putative imprinting control region. , 2002, Genome research.

[9]  Hirokazu Nagai,et al.  Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. , 2002, Blood.

[10]  P. Soloway,et al.  Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1 , 2002, Nature Genetics.

[11]  M. Toyota,et al.  Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors , 2002, Oncogene.

[12]  D. Barlow,et al.  Quantitative genetics: Turning up the heat on QTL mapping , 2002, Nature Reviews Genetics.

[13]  R. Weksberg,et al.  Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. , 2001, Human molecular genetics.

[14]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[15]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[16]  Karl Mechtler,et al.  Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins , 2001, Nature.

[17]  J. Ruijter,et al.  Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS. , 2001, Human molecular genetics.

[18]  A. Feinberg.  The two-domain hypothesis in Beckwith-Wiedemann syndrome. , 2000, The Journal of clinical investigation.

[19]  M. Meguro,et al.  Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome. , 2000, Human molecular genetics.

[20]  W. Schulz,et al.  Decreased expression of p57KIP2mRNA in human bladder cancer , 2000, British Journal of Cancer.

[21]  A. Feinberg,et al.  Hot-stop PCR: a simple and general assay for linear quantitation of allele ratios , 2000, Nature Genetics.

[22]  Jong-Yeon Shin,et al.  Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer , 2000, Experimental & Molecular Medicine.

[23]  C. Croce,et al.  Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[25]  C. Allis,et al.  Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. J. Driscoll,et al.  A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Feinberg,et al.  LIT1, an imprinted antisense RNA in the human KvLQT1 locus identified by screening for differentially expressed transcripts using monochromosomal hybrids. , 1999, Human molecular genetics.

[28]  A. Feinberg,et al.  Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[30]  R. DePinho,et al.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Tycko,et al.  Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. , 1997, American journal of human genetics.

[32]  P. Laird,et al.  COBRA: a sensitive and quantitative DNA methylation assay. , 1997, Nucleic acids research.

[33]  Y. Fukushima,et al.  An imprinted gene p57KIP2 is mutated in Beckwith–Wiedemann syndrome , 1996, Nature Genetics.

[34]  Y. Fukushima,et al.  Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. , 1996, Human molecular genetics.

[35]  T. Mukai,et al.  Genomic imprinting of p57KIP2, a cyclin–dependent kinase inhibitor, in mouse , 1995, Nature Genetics.

[36]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[37]  S. Elledge,et al.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. , 1995, Genes & development.

[38]  G. Bepler,et al.  Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Imamura,et al.  Characterization of 21 newly established esophageal cancer cell lines , 1992, Cancer.

[40]  C. Junien,et al.  Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.